{"entity":{"type":"insider","cik":"0001253886","url":"/insider/0001253886","json_url":"/insider/0001253886.json","name":"ENRIGHT PATRICK G","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":366,"n_filings":105,"first":"2005-02-09","last":"2026-02-06","span_basis":"filed_date"},"name_variants":[{"name":"ENRIGHT PATRICK G","source":"filing","n_filings":105,"first_seen":"2005-02-09","last_seen":"2026-02-06"}],"transactions":[{"id":6187614,"accession":"0001628280-26-005904","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001628280-26-005904","line_url":"/filing/0001628280-26-005904","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Veradermics, Inc","issuer_ticker":"MANE","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1075000.0,"shares_display":"1,075,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":18275000.0,"total_display":"18,275,000.00","total_whole":"18,275,000","shares_owned_after":2053474.0,"shares_owned_after_display":"2,053,474","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-05","filed_date":"2026-02-05","scope":"insider","n_lines":2},{"id":6036226,"accession":"0001193125-26-041248","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-041248","line_url":"/filing/0001193125-26-041248#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Fund, L.P.; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":49000.0,"shares_display":"49,000","price_per_share":3.8794,"price_display":"3.88","price_state":"stated","total_value":190090.6,"total_display":"190,090.60","total_whole":"190,091","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-04","filed_date":"2026-02-06","scope":"insider"},{"id":6036159,"accession":"0001193125-26-036387","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001193125-26-036387","line_url":"/filing/0001193125-26-036387#line-5","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27500.0,"shares_display":"27,500","price_per_share":4.2415,"price_display":"4.24","price_state":"stated","total_value":116641.25,"total_display":"116,641.25","total_whole":"116,641","shares_owned_after":49000.0,"shares_owned_after_display":"49,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-03","filed_date":"2026-02-03","scope":"insider"},{"id":6036156,"accession":"0001193125-26-036387","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-26-036387","line_url":"/filing/0001193125-26-036387#line-4","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27500.0,"shares_display":"27,500","price_per_share":4.246,"price_display":"4.25","price_state":"stated","total_value":116765.0,"total_display":"116,765.00","total_whole":"116,765","shares_owned_after":76500.0,"shares_owned_after_display":"76,500","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-02","filed_date":"2026-02-03","scope":"insider"},{"id":6036153,"accession":"0001193125-26-036387","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001193125-26-036387","line_url":"/filing/0001193125-26-036387#line-3","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":46000.0,"shares_display":"46,000","price_per_share":4.5435,"price_display":"4.54","price_state":"stated","total_value":209001.0,"total_display":"209,001.00","total_whole":"209,001","shares_owned_after":104000.0,"shares_owned_after_display":"104,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-30","filed_date":"2026-02-03","scope":"insider"},{"id":6036146,"accession":"0001193125-26-036387","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-036387","line_url":"/filing/0001193125-26-036387#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7739.0,"shares_display":"7,739","price_per_share":4.064,"price_display":"4.06","price_state":"stated","total_value":31451.296,"total_display":"31,451.30","total_whole":"31,451","shares_owned_after":4029245.0,"shares_owned_after_display":"4,029,245","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-23","filed_date":"2026-02-03","scope":"insider"},{"id":4702267,"accession":"0001193125-25-319649","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-319649","line_url":"/filing/0001193125-25-319649#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5882.0,"shares_display":"5,882","price_per_share":42.5,"price_display":"42.50","price_state":"stated","total_value":249985.0,"total_display":"249,985.00","total_whole":"249,985","shares_owned_after":5882.0,"shares_owned_after_display":"5,882","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-11","filed_date":"2025-12-15","scope":"insider"},{"id":4298189,"accession":"0001193125-25-238326","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-238326","line_url":"/filing/0001193125-25-238326","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":117255.0,"shares_display":"117,255","price_per_share":19.18917316958765,"price_display":"19.19","price_state":"stated","total_value":2250026.5,"total_display":"2,250,026.50","total_whole":"2,250,027","shares_owned_after":1832669.0,"shares_owned_after_display":"1,832,669","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-09","filed_date":"2025-10-14","scope":"insider","n_lines":2},{"id":4342006,"accession":"0000950170-25-090110","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-090110","line_url":"/filing/0000950170-25-090110","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40607.0,"shares_display":"40,607","price_per_share":22.3517,"price_display":"22.35","price_state":"stated","total_value":907635.4819,"total_display":"907,635.48","total_whole":"907,635","shares_owned_after":3596593.0,"shares_owned_after_display":"3,596,593","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-24","filed_date":"2025-06-25","scope":"insider","n_lines":2},{"id":4342001,"accession":"0000950170-25-090110","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-090110","line_url":"/filing/0000950170-25-090110","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":209393.0,"shares_display":"209,393","price_per_share":20.8683,"price_display":"20.87","price_state":"stated","total_value":4369675.9419,"total_display":"4,369,675.94","total_whole":"4,369,676","shares_owned_after":3569522.0,"shares_owned_after_display":"3,569,522","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-23","filed_date":"2025-06-25","scope":"insider","n_lines":2},{"id":2530763,"accession":"0001415889-24-024046","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-024046","line_url":"/filing/0001415889-24-024046#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"BioAge Labs, Inc.","issuer_ticker":"BIOA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":7200000.0,"total_display":"7,200,000.00","total_whole":"7,200,000","shares_owned_after":1710589.0,"shares_owned_after_display":"1,710,589","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-27","filed_date":"2024-09-27","scope":"insider"},{"id":2354148,"accession":"0001104659-24-100333","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-24-100333","line_url":"/filing/0001104659-24-100333#line-4","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Zenas BioPharma, Inc.","issuer_ticker":"ZBIO","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":440000.0,"shares_display":"440,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":7480000.0,"total_display":"7,480,000.00","total_whole":"7,480,000","shares_owned_after":774530.0,"shares_owned_after_display":"774,530","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-16","scope":"insider"},{"id":8296920,"accession":"0001209191-23-054904","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-054904","line_url":"/filing/0001209191-23-054904#line-3","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Lexeo Therapeutics, Inc.","issuer_ticker":"LXEO","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Partners IV, LLC; Longitude Venture Partners IV, L.P.; Tammenoms Bakker Juliet; ENRIGHT PATRICK G","owner_display_name":"Longitude Capital Partners IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":454545.0,"shares_display":"454,545","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":2567100.0,"shares_owned_after_display":"2,567,100","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-07","filed_date":"2023-11-09","scope":"insider"},{"id":8565661,"accession":"0001765581-23-000078","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001765581-23-000078","line_url":"/filing/0001765581-23-000078#line-2","is_derivative":false,"issuer_cik":"0001232524","issuer_name":"Jazz Pharmaceuticals plc","issuer_ticker":"JAZZ","issuer_name_source":null,"issuer_url":"/issuer/0001232524","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1241.0,"shares_display":"1,241","price_per_share":138.1585,"price_display":"138.16","price_state":"stated","total_value":171454.6985,"total_display":"171,454.70","total_whole":"171,455","shares_owned_after":20946.0,"shares_owned_after_display":"20,946","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-14","filed_date":"2023-08-15","scope":"insider"},{"id":8456993,"accession":"0000899243-23-004345","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-23-004345","line_url":"/filing/0000899243-23-004345#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1714285.0,"shares_display":"1,714,285","price_per_share":7.0,"price_display":"7.00","price_state":"stated","total_value":11999995.0,"total_display":"11,999,995.00","total_whole":"11,999,995","shares_owned_after":1714285.0,"shares_owned_after_display":"1,714,285","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-06","filed_date":"2023-02-08","scope":"insider"},{"id":6529541,"accession":"0001765581-22-000126","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001765581-22-000126","line_url":"/filing/0001765581-22-000126","is_derivative":false,"issuer_cik":"0001232524","issuer_name":"Jazz Pharmaceuticals plc","issuer_ticker":"JAZZ","issuer_name_source":null,"issuer_url":"/issuer/0001232524","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6974.0,"shares_display":"6,974","price_per_share":150.45370321193002,"price_display":"150.45","price_state":"stated","total_value":1049264.1262,"total_display":"1,049,264.13","total_whole":"1,049,264","shares_owned_after":21181.0,"shares_owned_after_display":"21,181","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-22","filed_date":"2022-11-25","scope":"insider","n_lines":3},{"id":6584763,"accession":"0001765581-22-000084","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001765581-22-000084","line_url":"/filing/0001765581-22-000084#line-2","is_derivative":false,"issuer_cik":"0001232524","issuer_name":"Jazz Pharmaceuticals plc","issuer_ticker":"JAZZ","issuer_name_source":null,"issuer_url":"/issuer/0001232524","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1089.0,"shares_display":"1,089","price_per_share":152.3264,"price_display":"152.33","price_state":"stated","total_value":165883.4496,"total_display":"165,883.45","total_whole":"165,883","shares_owned_after":24086.0,"shares_owned_after_display":"24,086","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-08","filed_date":"2022-08-09","scope":"insider"},{"id":6691184,"accession":"0000899243-22-015325","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-015325","line_url":"/filing/0000899243-22-015325#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Inozyme Pharma, Inc.","issuer_ticker":"INZY","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Venture Partners III, L.P.; Longitude Capital Partners III, LLC; ENRIGHT PATRICK G; Tammenoms Bakker Juliet","owner_display_name":"Longitude Venture Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1355000.0,"shares_display":"1,355,000","price_per_share":3.69,"price_display":"3.69","price_state":"stated","total_value":4999950.0,"total_display":"4,999,950.00","total_whole":"4,999,950","shares_owned_after":4174379.0,"shares_owned_after_display":"4,174,379","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-04-19","filed_date":"2022-04-21","scope":"insider"},{"id":6691080,"accession":"0000899243-22-013596","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-013596","line_url":"/filing/0000899243-22-013596#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":333333.0,"shares_display":"333,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":3429927.0,"shares_owned_after_display":"3,429,927","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-10","filed_date":"2022-04-05","scope":"insider"},{"id":6531980,"accession":"0000899243-22-004271","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-22-004271","line_url":"/filing/0000899243-22-004271#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Sierra Oncology, Inc.","issuer_ticker":"SRRA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Prime Fund, L.P.; Longitude Prime Partners, LLC; ENRIGHT PATRICK G; Tammenoms Bakker Juliet; Longitude Venture Partners III, L.P.; Longitude Capital Partners III, LLC","owner_display_name":"Longitude Prime Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":175000.0,"shares_display":"175,000","price_per_share":27.0,"price_display":"27.00","price_state":"stated","total_value":4725000.0,"total_display":"4,725,000.00","total_whole":"4,725,000","shares_owned_after":175000.0,"shares_owned_after_display":"175,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-02","filed_date":"2022-02-02","scope":"insider"},{"id":4305930,"accession":"0000899243-21-029105","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-029105","line_url":"/filing/0000899243-21-029105#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"RAPID MICRO BIOSYSTEMS, INC.","issuer_ticker":"RPID","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Partners II, LLC; Longitude Prime Partners, LLC; ENRIGHT PATRICK G; Longitude Prime Fund, L.P.; Longitude Venture Partners II, L.P.; Tammenoms Bakker Juliet","owner_display_name":"Longitude Capital Partners II, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":150000.0,"shares_owned_after_display":"150,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-07-19","filed_date":"2021-07-20","scope":"insider"},{"id":4667718,"accession":"0001209191-21-033809","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-033809","line_url":"/filing/0001209191-21-033809#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Vera Therapeutics, Inc.","issuer_ticker":"VERA","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Class A Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":909090.0,"shares_display":"909,090","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":9999990.0,"total_display":"9,999,990.00","total_whole":"9,999,990","shares_owned_after":3096594.0,"shares_owned_after_display":"3,096,594","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-18","filed_date":"2021-05-18","scope":"insider"},{"id":4708239,"accession":"0000899243-21-019166","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-21-019166","line_url":"/filing/0000899243-21-019166#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Talaris Therapeutics, Inc.","issuer_ticker":"TALS","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Tammenoms Bakker Juliet; Longitude Capital Partners III, LLC; ENRIGHT PATRICK G; Longitude Venture Partners III, L.P.","owner_display_name":"Tammenoms Bakker Juliet","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":235000.0,"shares_display":"235,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":3995000.0,"total_display":"3,995,000.00","total_whole":"3,995,000","shares_owned_after":3220775.0,"shares_owned_after_display":"3,220,775","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-11","filed_date":"2021-05-11","scope":"insider"},{"id":2768519,"accession":"0001765581-20-000120","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001765581-20-000120","line_url":"/filing/0001765581-20-000120","is_derivative":false,"issuer_cik":"0001232524","issuer_name":"Jazz Pharmaceuticals plc","issuer_ticker":"JAZZ","issuer_name_source":null,"issuer_url":"/issuer/0001232524","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9929.0,"shares_display":"9,929","price_per_share":146.71549408802497,"price_display":"146.72","price_state":"stated","total_value":1456738.1408,"total_display":"1,456,738.14","total_whole":"1,456,738","shares_owned_after":21991.0,"shares_owned_after_display":"21,991","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-12","filed_date":"2020-11-13","scope":"insider","n_lines":3},{"id":2732708,"accession":"0000899243-20-029109","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-029109","line_url":"/filing/0000899243-20-029109#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Eargo, Inc.","issuer_ticker":"EAR","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Partners IV, LLC; Longitude Venture Partners IV, L.P.; ENRIGHT PATRICK G","owner_display_name":"Longitude Capital Partners IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":233333.0,"shares_display":"233,333","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":4199994.0,"total_display":"4,199,994.00","total_whole":"4,199,994","shares_owned_after":3918691.0,"shares_owned_after_display":"3,918,691","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-10-20","filed_date":"2020-10-22","scope":"insider"},{"id":3239630,"accession":"0000899243-20-023790","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-023790","line_url":"/filing/0000899243-20-023790","is_derivative":false,"issuer_cik":"0001183765","issuer_name":"Molecular Templates, Inc.","issuer_ticker":"MTEM","issuer_name_source":null,"issuer_url":"/issuer/0001183765","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners III, LLC; Longitude Venture Partners III, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3496.0,"shares_display":"3,496","price_per_share":10.7461,"price_display":"10.75","price_state":"stated","total_value":37568.3656,"total_display":"37,568.37","total_whole":"37,568","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-08-28","filed_date":"2020-09-01","scope":"insider","n_lines":2},{"id":2101106,"accession":"0000899243-20-020572","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-020572","line_url":"/filing/0000899243-20-020572#line-3","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Inozyme Pharma, Inc.","issuer_ticker":"INZY","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Venture Partners III, L.P.; Tammenoms Bakker Juliet; ENRIGHT PATRICK G; Longitude Capital Partners III, LLC","owner_display_name":"Longitude Venture Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":625000.0,"shares_display":"625,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":2819379.0,"shares_owned_after_display":"2,819,379","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-28","filed_date":"2020-07-28","scope":"insider"},{"id":3111754,"accession":"0000899243-20-019123","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-019123","line_url":"/filing/0000899243-20-019123#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"89bio, Inc.","issuer_ticker":"ETNB","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Venture Partners III, L.P.; Longitude Capital Partners III, LLC; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":109090.0,"shares_display":"109,090","price_per_share":27.5,"price_display":"27.50","price_state":"stated","total_value":2999975.0,"total_display":"2,999,975.00","total_whole":"2,999,975","shares_owned_after":2600877.0,"shares_owned_after_display":"2,600,877","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-10","filed_date":"2020-07-14","scope":"insider"},{"id":2132780,"accession":"0000899243-20-014612","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-20-014612","line_url":"/filing/0000899243-20-014612#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7840.0,"shares_display":"7,840","price_per_share":0.0,"price_display":null,"price_state":"not-stated","total_value":0.0,"total_display":null,"total_whole":null,"shares_owned_after":78401.0,"shares_owned_after_display":"78,401","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-05-27","filed_date":"2020-05-29","scope":"insider"},{"id":2986242,"accession":"0000899243-20-009016","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-009016","line_url":"/filing/0000899243-20-009016#line-3","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16213.0,"shares_display":"16,213","price_per_share":11.0618,"price_display":"11.06","price_state":"stated","total_value":179344.9634,"total_display":"179,344.96","total_whole":"179,345","shares_owned_after":70561.0,"shares_owned_after_display":"70,561","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-18","filed_date":"2020-03-19","scope":"insider"},{"id":2986236,"accession":"0000899243-20-009016","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-20-009016","line_url":"/filing/0000899243-20-009016","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Aimmune Therapeutics, Inc.","issuer_ticker":"AIMT","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, $0.0001 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":108787.0,"shares_display":"108,787","price_per_share":11.404859955693235,"price_display":"11.40","price_state":"stated","total_value":1240700.5,"total_display":"1,240,700.50","total_whole":"1,240,701","shares_owned_after":6113134.0,"shares_owned_after_display":"6,113,134","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-17","filed_date":"2020-03-19","scope":"insider","n_lines":2},{"id":2317381,"accession":"0001567619-20-001010","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-20-001010","line_url":"/filing/0001567619-20-001010","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Aptinyx Inc.","issuer_ticker":"APTX","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":261667.0,"shares_display":"261,667","price_per_share":3.0,"price_display":"3.00","price_state":"stated","total_value":785001.0,"total_display":"785,001.00","total_whole":"785,001","shares_owned_after":3356746.0,"shares_owned_after_display":"3,356,746","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-01-10","filed_date":"2020-01-14","scope":"insider","n_lines":2},{"id":9204689,"accession":"0000899243-19-028574","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-028574","line_url":"/filing/0000899243-19-028574#line-1","is_derivative":false,"issuer_cik":"0001674099","issuer_name":"Molecular Templates, Inc.","issuer_ticker":"MTEM","issuer_name_source":null,"issuer_url":"/issuer/0001674099","owner_cik":null,"owner_name":"ENRIGHT PATRICK G; Longitude Capital Partners III, LLC; Longitude Venture Partners III, L.P.; Tammenoms Bakker Juliet","owner_display_name":"ENRIGHT PATRICK G","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":937500.0,"shares_display":"937,500","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":7500000.0,"total_display":"7,500,000.00","total_whole":"7,500,000","shares_owned_after":4199035.0,"shares_owned_after_display":"4,199,035","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-25","filed_date":"2019-12-05","scope":"insider"},{"id":7967368,"accession":"0000899243-19-028242","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-028242","line_url":"/filing/0000899243-19-028242#line-1","is_derivative":false,"issuer_cik":"0001183765","issuer_name":"Molecular Templates, Inc.","issuer_ticker":"MTEM","issuer_name_source":null,"issuer_url":"/issuer/0001183765","owner_cik":null,"owner_name":"Longitude Venture Partners III, L.P.; Longitude Capital Partners III, LLC; Tammenoms Bakker Juliet; ENRIGHT PATRICK G","owner_display_name":"Longitude Venture Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":937000.0,"shares_display":"937,000","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":7496000.0,"total_display":"7,496,000.00","total_whole":"7,496,000","shares_owned_after":4198535.0,"shares_owned_after_display":"4,198,535","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-25","filed_date":"2019-11-27","scope":"insider"},{"id":7939022,"accession":"0000899243-19-027219","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-027219","line_url":"/filing/0000899243-19-027219#line-1","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"89bio, Inc.","issuer_ticker":"ETNB","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Capital Partners III, LLC; ENRIGHT PATRICK G; Tammenoms Bakker Juliet; Longitude Venture Partners III, L.P.","owner_display_name":"Longitude Capital Partners III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":575000.0,"shares_display":"575,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":9200000.0,"total_display":"9,200,000.00","total_whole":"9,200,000","shares_owned_after":575000.0,"shares_owned_after_display":"575,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-11","filed_date":"2019-11-13","scope":"insider"},{"id":8717752,"accession":"0001765581-19-000082","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001765581-19-000082","line_url":"/filing/0001765581-19-000082#line-2","is_derivative":false,"issuer_cik":"0001232524","issuer_name":"Jazz Pharmaceuticals plc","issuer_ticker":"JAZZ","issuer_name_source":null,"issuer_url":"/issuer/0001232524","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":726.0,"shares_display":"726","price_per_share":135.6489,"price_display":"135.65","price_state":"stated","total_value":98481.1014,"total_display":"98,481.10","total_whole":"98,481","shares_owned_after":17663.0,"shares_owned_after_display":"17,663","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-08-09","filed_date":"2019-08-12","scope":"insider"},{"id":5981355,"accession":"0000899243-18-028081","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-028081","line_url":"/filing/0000899243-18-028081#line-2","is_derivative":false,"issuer_cik":"0001253886","issuer_name":"Axonics Modulation Technologies, Inc.","issuer_ticker":"AXNX","issuer_name_source":null,"issuer_url":"/issuer/0001253886","owner_cik":null,"owner_name":"Longitude Venture Partners III, L.P.; Longitude Capital Partners III, LLC; ENRIGHT PATRICK G","owner_display_name":"Longitude Venture Partners III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":533333.0,"shares_display":"533,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":7999995.0,"total_display":"7,999,995.00","total_whole":"7,999,995","shares_owned_after":2933333.0,"shares_owned_after_display":"2,933,333","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-11-02","filed_date":"2018-11-02","scope":"insider"},{"id":6021204,"accession":"0001209191-18-052151","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-052151","line_url":"/filing/0001209191-18-052151#line-1","is_derivative":false,"issuer_cik":"0001183765","issuer_name":"Molecular Templates, Inc.","issuer_ticker":"MTEM","issuer_name_source":null,"issuer_url":"/issuer/0001183765","owner_cik":null,"owner_name":"Longitude Capital Partners III, LLC; ENRIGHT PATRICK G; Tammenoms Bakker Juliet; Longitude Venture Partners III, L.P.","owner_display_name":"Longitude Capital Partners III, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":365000.0,"shares_display":"365,000","price_per_share":5.5,"price_display":"5.50","price_state":"stated","total_value":2007500.0,"total_display":"2,007,500.00","total_whole":"2,007,500","shares_owned_after":3261535.0,"shares_owned_after_display":"3,261,535","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-09-21","filed_date":"2018-09-25","scope":"insider"},{"id":6458702,"accession":"0001232524-18-000167","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001232524-18-000167","line_url":"/filing/0001232524-18-000167#line-6","is_derivative":false,"issuer_cik":"0001232524","issuer_name":"Jazz Pharmaceuticals plc","issuer_ticker":"JAZZ","issuer_name_source":null,"issuer_url":"/issuer/0001232524","owner_cik":"0001253886","owner_name":"ENRIGHT PATRICK G","owner_display_name":"ENRIGHT PATRICK G","owner_url":"/insider/0001253886","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7086.0,"shares_display":"7,086","price_per_share":168.8633,"price_display":"168.86","price_state":"stated","total_value":1196565.3438,"total_display":"1,196,565.34","total_whole":"1,196,565","shares_owned_after":17469.0,"shares_owned_after_display":"17,469","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-09-06","filed_date":"2018-09-07","scope":"insider"}],"collapsed":true,"next_cursor":"2018-09-06|6458702","ledger_fault":false,"count":{"value":321,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":35,"open_market":true},{"code":"S","label":"Open-market sale","n":286,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":321},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001380106","name":"RAPID MICRO BIOSYSTEMS, INC.","url":"/issuer/0001380106","role":"Ten percent owner","n_filings":3,"first_seen":"2021-07-20","last_seen":"2026-02-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001827635","name":"Veradermics, Inc","url":"/issuer/0001827635","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2026-02-05","last_seen":"2026-02-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001831828","name":"Vera Therapeutics, Inc.","url":"/issuer/0001831828","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2021-05-18","last_seen":"2025-12-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001953926","name":"Zenas BioPharma, Inc.","url":"/issuer/0001953926","role":"Director","n_filings":2,"first_seen":"2024-09-16","last_seen":"2025-10-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001709941","name":"BioAge Labs, Inc.","url":"/issuer/0001709941","role":"Director","n_filings":1,"first_seen":"2024-09-27","last_seen":"2024-09-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001907108","name":"Lexeo Therapeutics, Inc.","url":"/issuer/0001907108","role":"Ten percent owner","n_filings":1,"first_seen":"2023-11-09","last_seen":"2023-11-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001232524","name":"Jazz Pharmaceuticals plc","url":"/issuer/0001232524","role":"Director, Ten percent owner","n_filings":45,"first_seen":"2009-09-03","last_seen":"2023-08-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001693011","name":"Inozyme Pharma, Inc.","url":"/issuer/0001693011","role":"Ten percent owner","n_filings":2,"first_seen":"2020-07-28","last_seen":"2022-04-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001290149","name":"Sierra Oncology, Inc.","url":"/issuer/0001290149","role":"Ten percent owner","n_filings":1,"first_seen":"2022-02-02","last_seen":"2022-02-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001827506","name":"Talaris Therapeutics, Inc.","url":"/issuer/0001827506","role":"Ten percent owner","n_filings":1,"first_seen":"2021-05-11","last_seen":"2021-05-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001719395","name":"Eargo, Inc.","url":"/issuer/0001719395","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-22","last_seen":"2020-10-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001183765","name":"Molecular Templates, Inc.","url":"/issuer/0001183765","role":"Director, Ten percent owner","n_filings":7,"first_seen":"2005-02-09","last_seen":"2020-09-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001785173","name":"89bio, Inc.","url":"/issuer/0001785173","role":"Ten percent owner","n_filings":2,"first_seen":"2019-11-13","last_seen":"2020-07-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001631650","name":"Aimmune Therapeutics, Inc.","url":"/issuer/0001631650","role":"Director, Ten percent owner","n_filings":7,"first_seen":"2015-08-11","last_seen":"2020-05-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001674365","name":"Aptinyx Inc.","url":"/issuer/0001674365","role":"Director","n_filings":2,"first_seen":"2018-06-26","last_seen":"2020-01-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001603756","name":"Axonics Modulation Technologies, Inc.","url":"/issuer/0001603756","role":"Ten percent owner","n_filings":1,"first_seen":"2018-11-02","last_seen":"2018-11-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001595585","name":"Tricida, Inc.","url":"/issuer/0001595585","role":"Ten percent owner","n_filings":1,"first_seen":"2018-07-02","last_seen":"2018-07-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001267565","name":"COLLEGIUM PHARMACEUTICAL, INC","url":"/issuer/0001267565","role":"Ten percent owner","n_filings":2,"first_seen":"2015-05-14","last_seen":"2017-12-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001479419","name":"Kala Pharmaceuticals, Inc.","url":"/issuer/0001479419","role":"Ten percent owner","n_filings":1,"first_seen":"2017-07-27","last_seen":"2017-07-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001088856","name":"CORCEPT THERAPEUTICS INC","url":"/issuer/0001088856","role":"Director, Ten percent owner","n_filings":14,"first_seen":"2009-02-10","last_seen":"2017-03-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001434868","name":"Esperion Therapeutics, Inc.","url":"/issuer/0001434868","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2013-07-01","last_seen":"2015-03-23"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001253886","retrieved_at":"2026-08-27T00:38:36+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}